The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.

BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers ...

Mavacamten is a selective, reversible, allosteric cardiac myosin inhibitor. It is approved under the brand name Camzyos ® for the treatment of adults with symptomatic New York Heart Association class ...

Princeton, New Jersey Wednesday, January 14, 2026, 12:00 Hrs [IST] ...

Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) ...

Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...

Plans linked to the former Nottinghamshire Fire and Rescue Service headquarters at Bestwood are set to return to councillors ...

Background Annually, 4% of the global population undergoes non-cardiac surgery, with 30% of those patients having at least ...

Another alternative to the 4% rule is the dynamic spending plan. Instead of simply assuming you will spend 4% of your assets ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical ...

CBSE Class 12 practical examinations for the 2026 board exams are being scheduled in many schools during the second half of ...